NCT01736683 - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2012

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions

AnemiaMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaLow to Intermediate-1 MDSMyelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG

Sotatercept

Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

Trial Locations (20)

10032

Columbia University Medical Center/New York-Presbyterian Hospital, New York

11042

Monter Cancer Center, North Shore LIJ Health Systems, Lake Success

13273

Institute Paoli-Calmettes Service Haematology, BP 156,

21231

Johns Hopkins, Baltimore

23502

Virginia Oncology Associates, Norfolk

31059

CHU Purpan, Toulouse

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37203

Sarah Cannon Research Inst, Nashville

44093

CHRU Nantes, Nantes

44195

The Cleveland Clinic Foundation Hematology and Medical Oncology Rm 35, Cleveland

59037

CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille

75679

Hopital Cochin Hematologie, Paris

75702

Texas Oncology, P.A. - Tyler, Tyler

78229

University of Texas Health Science Center at San Antonio, San Antonio

78681

Texas Oncology Round Rock Cancer Center - Round Rock, Round Rock

79038

Centre Henri Becquerel, Rouen

80218

Rocky Mountain Cancer Center-Midtown, Denver

93009

Centre Hospitalier Universitaire d'Avicennes, Bobigny

98902

Yakima Valley Memorial Hospital/ North Star Lodge, Yakima

02215

Dana-Farber / Harvard Cancer Institute, Boston

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY